Deals this week: NicOx, FibroGen, Omeros - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Deals this week: NicOx, FibroGen, Omeros

17 Aug 2017 (Last Updated August 17th, 2017 18:30)

NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total.

NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total.

Based in France, NicOx is a pharmaceutical company focused on the development of treatments for ophthalmic conditions. The company plans to use the funds to progress the development of its products and for general corporate purposes.

US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total.

The company plans to use the funds towards product development, clinical programmes and commercialisation activities.

"US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total."

Omeros has announced a public offering of three million common stock shares priced at $22.75 a share to raise $68.25m.

The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.

Apellis Pharmaceuticals has raised $60m in a Series E funding round led by Sectoral Asset Management.

Based in the US, the clinical-stage biopharmaceutical company plans to use the funds to progress the development of its APL-2 drug.